Venetoclax Adverse Event Report 2018

$19.99

This report includes data from the FDA’s Adverse Events Reports for 2018.  We removed reports where the subject of the report was taking only this drug. This report provides the following fields:

  • ID
  • Patient Summary
  • Patient Gender
  • Patient Age
  • Drug Products
  • Drug Reactions

Description

Venetoclax is used to treat chronic lymphocytic leukemia or small lymphocytic leukemia in adults with or without 17p deletion (a specific genetic marker). Venetoclax is sometimes used in combination with rituximab to treat these conditions. Venetoclax is also used in combination with azacitidine, decitabine, or cytarabine to treat acute myeloid leukemia. This combination is for use in adults who are 75 years or older, or who cannot use standard chemotherapy due to other medical conditions. Venetoclax is sometimes given after other treatments have failed. Venetoclax may also be used for purposes not listed in this medication guide.https://www.drugs.com/mtm/venetoclax.html

Contact US

484-352-2642

What is an Adverse Event Report?

The FDA Adverse Event Reporting System (FAERS) is a database that contains adverse event reports, medication error reports and product quality complaints resulting in adverse events that were submitted to FDA.